U.S. markets open in 3 hours 4 minutes
  • S&P Futures

    3,827.75
    -14.75 (-0.38%)
     
  • Dow Futures

    30,689.00
    -153.00 (-0.50%)
     
  • Nasdaq Futures

    13,518.00
    +32.50 (+0.24%)
     
  • Russell 2000 Futures

    2,125.40
    -20.40 (-0.95%)
     
  • Crude Oil

    52.87
    +0.26 (+0.49%)
     
  • Gold

    1,841.90
    -9.00 (-0.49%)
     
  • Silver

    25.32
    -0.22 (-0.87%)
     
  • EUR/USD

    1.2127
    -0.0041 (-0.34%)
     
  • 10-Yr Bond

    1.0400
    0.0000 (0.00%)
     
  • Vix

    25.08
    +1.89 (+8.15%)
     
  • GBP/USD

    1.3730
    -0.0002 (-0.01%)
     
  • USD/JPY

    103.7880
    +0.1610 (+0.16%)
     
  • BTC-USD

    31,560.07
    -811.78 (-2.51%)
     
  • CMC Crypto 200

    634.46
    -5.46 (-0.85%)
     
  • FTSE 100

    6,608.25
    -45.76 (-0.69%)
     
  • Nikkei 225

    28,635.21
    +89.03 (+0.31%)
     

Ardelyx to Present at the Jefferies Virtual London Healthcare Conference

·1 min read

FREMONT, Calif., Nov. 10, 2020 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases, today announced that Mike Raab, president and chief executive officer of Ardelyx, will participate in a fireside chat at the Jefferies Virtual London Healthcare Conference on Tuesday, November 17, 2020 at 1:10 p.m. ET.

Ardelyx logo (PRNewsFoto/Ardelyx) (PRNewsfoto/Ardelyx)
Ardelyx logo (PRNewsFoto/Ardelyx) (PRNewsfoto/Ardelyx)

To access the live webcast of Ardelyx's presentation please visit the Events & Presentations page within the Investor section of the Ardelyx website at https://ir.ardelyx.com/events-and-presentations. A replay of the webcast will be available on the Ardelyx website for 60 days following the presentation.

About Ardelyx, Inc.
Ardelyx is focused on developing innovative first-in-class medicines to enhance the lives of patients with kidney and cardiovascular diseases. Ardelyx is advancing tenapanor, a novel product candidate to control serum phosphorus in adult patients with CKD on dialysis, for which the company's NDA is currently under review by the FDA, with a PDUFA goal date of April 29, 2021. Ardelyx is also advancing RDX013, a potassium secretagogue program, for the potential treatment of high potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease. In addition, Ardelyx received FDA approval of IBSRELA® (tenapanor) on September 12, 2019. Ardelyx has established agreements with Kyowa Kirin in Japan, Fosun Pharma in China and Knight Therapeutics in Canada for the development and commercialization of tenapanor in the respective territories.

Cision
Cision

View original content to download multimedia:http://www.prnewswire.com/news-releases/ardelyx-to-present-at-the-jefferies-virtual-london-healthcare-conference-301169441.html

SOURCE Ardelyx